Subject to final approval by the European Commission, Seqirus plans to launch the vaccine as FLUCELVAX® TETRA1 in Europe for the 2019/20 influenza season. 19 Oct 2018 Seqirus, a global leader in...

Human Vaccines Project and Seqirus Partner to Advance Universal Flu Vaccine Research New York, NY and Maidenhead, UK — 06/26/2018 The Human Vaccines Project, a nonprofit public-private...

The project is intended to significantly improve access to antivenoms by combining a large antivenom donation, healthcare worker training, with a purpose-built distribution and product management...

Seqirus partners with American Nurse Practitioner Foundation, American Pharmacists Association and Physician Assistant Foundation to drive conversation around flu prevention in adults 65 and older...

This decision comes after Public Health England declared that conventional non-adjuvanted influenza vaccines provided little or no protection for adults aged 65 years and over in the 2016-17 flu...

Nearly a hundred new high tech jobs are to be created at the Liverpool manufacturing site of Seqirus as a result of major new investment announced today. 08 Nov 2017 New fill-and-finish facility...

Seqirus announced today that the accelerated development of cell-based manufacturing technology at its manufacturing facility in Holly Springs, North Carolina, has delivered a four-fold increase...

Seqirus is now shipping its portfolio of over 50 million doses of influenza vaccines to the U.S. market in preparation for the upcoming 2017-2018 influenza season. 20 Jul 2017 Seqirus is now...

In an industry first, Seqirus has successfully produced cell-based influenza vaccine at commercial scale using a candidate vaccine virus (CVV) that has been isolated and grown in cells, rather...

Today the world’s no. 2 influenza vaccine provider, Seqirus, announced a £22.1m investment for its UK manufacturing site in Liverpool. 25 Feb 2017 The company, which is part of global...